Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Interest Expense is the amount reported by a company or individual as an expense for borrowed money. Vir Biotechnology's interest expense for the
three
months ended in Jun. 2026 was MXN 0 Mil.
Its interest expense for the trailing twelve months (TTM) ended in Jun. 2026 was MXN0 Mil.
Vir Biotechnology (MEX:VIR) Interest Expense Explanation
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense. The higher, the better.
Vir Biotechnology's Interest Coverage for the quarter that ended in Jun. 2026 is calculated as
GuruFocus does not calculate Vir Biotechnology's interest coverage with the available data.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
The higher the ratio, the stronger the company's financial strength is.
Good Sign:
Ben Graham prefers companies' interest coverage to be at least 5. Vir Biotechnology Inc has enough cash to cover all of its debt. Its financial situation is stable.
Vir Biotechnology Interest Expense Historical Data
* Premium members only.
The historical data trend for Vir Biotechnology's Interest Expense can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Interest Expense is the amount reported by a company or individual as an expense for borrowed money.
Interest Expense for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was MXN0 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Vir Biotechnology (MEX:VIR) has a Interest Expense of MXN0 Mil as of Jun. 2026. Interest Expense is the amount a company pays on its long-term debt. View historical data on Vir Biotechnology and its competitors.
Is Vir Biotechnology's Interest Expense too high?
Vir Biotechnology's current Interest Expense is MXN0 Mil. Overall, Vir Biotechnology has a GF Score™ of 52/100, reflecting its overall financial health beyond just this single metric.
How does Vir Biotechnology's Interest Expense compare to AVBP and XNCR?
Vir Biotechnology's Interest Expense of MXN0 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Interest Expense for a Biotechnology company?
A good Interest Expense depends on the Biotechnology industry context. However, Interest Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Interest Expense mean?
A high Interest Expense can signal that a stock is expensive relative to its fundamentals. Interest Expense is the amount a company pays on its long-term debt. View historical data on Vir Biotechnology and its competitors. Vir Biotechnology's current Interest Expense is MXN0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vir Biotechnology stock overvalued right now?
Vir Biotechnology (MEX:VIR) has a current Interest Expense of MXN0 Mil. The stock's GF Value™ is MXN755.16, compared to a current price of MXN170.00 — trading 77.5% below its estimated fair value. The current Interest Expense is MXN0 Mil. Vir Biotechnology's overall GF Score™ is 52/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Interest Expense calculated?
Interest Expense is calculated from a company's financial statements. For Vir Biotechnology (MEX:VIR), the current Interest Expense is MXN0 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Vir Biotechnology (MEX:VIR) Overvalued in 2026?
Based on GuruFocus' analysis, Vir Biotechnology stock appears to be undervalued.
The current stock price of MXN170.00 is trading 77.5% below its estimated GF Value™ of MXN755.16.
Key valuation signals for MEX:VIR:
Interest Expense: MXN0 Mil
GF Value™: MXN755.16 vs. price of MXN170.00 (77.5% below fair value)
No single metric tells the full story. See the MEX:VIR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Vir Biotechnology Inc is a clinical-stage biopharmaceutical company focused on powering the immune system by discovering and developing medicines for serious infectious diseases and cancer. The company uses its capabilities in antibody discovery and engineering, coupled with its proprietary AI engine dAIsY system, and the PRO-XTEN masking platform, to quickly and effectively discover and optimize potential new medicines. Its clinical development pipeline consists of investigational therapies like Tobevibart + elebsiran targeting the hepatitis delta virus (HDV), preclinical antibody candidates targeting HIV, and VIR-5500, VIR-5818, VIR-5525, and 7 PRO-XTEN programs targeting multiple solid tumors. Currently, the company generates revenue mainly by issuing license rights and through grants.
52GF Score
Get the complete analysis for MEX:VIR
Interest Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MEX:VIR has been successfully added to your 
